Literature DB >> 3014366

Down-regulation of growth hormone releasing factor receptors following continuous infusion of growth hormone releasing factor in vivo.

W B Wehrenberg, H Seifert, L M Bilezikjian, W Vale.   

Abstract

The in vivo chronic infusion of growth hormone releasing factor (GRF) results in a loss of the pituitary growth hormone (GH) response to GRF as well as in a substantial depletion of pituitary GH content. To evaluate if the loss in response is due to the down-regulation of GRF receptors the specific GRF binding capacity of pituitary homogenates prepared from rats infused with saline or GRF (1 or 15 micrograms/h for 24 h) was determined. The pituitary binding capacity of animals infused with GRF was significantly reduced as compared to animals infused with saline.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014366     DOI: 10.1159/000124538

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  4 in total

1.  Growth hormone response to long-term GH-RH administration in lambs.

Authors:  A Pérez-Romero; M A Rol De Lama; B Granados; E Vara; I Vázquez González; C Ariznavarreta; J A Tresguerres
Journal:  J Physiol Biochem       Date:  2000-06       Impact factor: 4.158

2.  Binding and internalization of gold-conjugated somatostatin and growth hormone-releasing hormone in cultured rat somatotropes.

Authors:  R Mentlein; C Buchholz; B Krisch
Journal:  Cell Tissue Res       Date:  1989-11       Impact factor: 5.249

3.  The effects of a continuous infusion of hexarelin on pulsatile growth hormone release, growth axis and galanin gene expression and on the response of the growth axis to growth hormone-releasing hormone.

Authors:  L K Conley; R S Brogan; A Giustina; W B Wehrenberg
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

Review 4.  A Comparative Update on the Neuroendocrine Regulation of Growth Hormone in Vertebrates.

Authors:  Emilio J Vélez; Suraj Unniappan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-23       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.